At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 76 enrolled
Drug / intervention
Blinatumomab (MT103)biological
Likely dose
Blinatumomab (MT103) 120 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-center Phase I Study to Investigate the Tolerability and Safety of a Continuous Infusion of the Bispecific T-cell Engager MT103 in Patients With Relapsed Non-Hodgkin's Lymphoma (NHL)
In Brief
A Phase 1 clinical trial evaluating Blinatumomab (MT103) for Non-Hodgkin's Lymphoma, Relapsed. Completed, enrolled 76 participants across 5 sites.
Detailed Summary
The purpose of this study is to determine whether a continuous infusion of Blinatumomab (MT103) is safe in the treatment of relapsed Non-Hodgkin's Lymphoma. Furthermore, the study is intended to provide pharmacokinetic and pharmacodynamic data of Blinatumomab as well as to get first indication of tumour activity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin's Lymphoma, Relapsed
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2004
First PostedJan 2006
Primary CompletionAug 2011
Study CompletionApr 2012
TodayJul 2026
First PostedJan 11, 2006
Enrollment StartJun 1, 2004
Primary CompletionAug 1, 2011
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 20.5 years ago
Interventions
Blinatumomab (MT103)biological
Doses from 0.5 to 120 µg/m\^2/24hours by continuous intravenous infusion